Crossmark

Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1007/s40618-019-01019-4

Published Online: 2019-02-14

Published Print: 2019-09-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dicembrini, I.

Giannini, S.

Ragghianti, B.

Mannucci, E.

Monami, M.
License Information

Text and Data Mining valid from 2019-02-14

Version of Record valid from 2019-02-14
More Information

Article History

Received: 28 October 2018

Accepted: 7 February 2019

First Online: 14 February 2019

Compliance with ethical standards

:

: Matteo Monami has received speaking fees from Bristol Myers Squibb, Eli-Lilly, Merck, Novonordisk, Merck, and Takeda, and research grants from Bristol Myers Squibb. Benedetta Ragghianti and Stefano Giannini have no conflict of interests.

: This article does not contain any studies with human participants or animals performed by any of the authors.

: This paper did not involve patients enrolled by any of the authors.

Document is current

Any future updates will be listed below